Mortality with Paclitaxel-Coated Devices in Peripheral Artery Disease

Interim analysis of a multicenter, randomized, clinical trial (Swedish Drug Elution Trial in Peripheral Arterial Disease) between November 5, 2014, and December 10, 2018. About one-half almost 2300 patients were treated with paclitaxel-coated devices uncoated devices. Approximately 25% died each group during mean follow-up 2.5 years. During the entire period, there was no significant difference incidence death treatment groups among chronic limb-threatening ischemia (about 33% group) or those intermittent claudication 10% group). In this randomized which received endovascular devices, 1 to 4 years follow-up.